Human Herpesvirus 8 Clinical Trial
Official title:
Suppression of Oral Shedding of Human Herpesvirus 8 (HHV-8) With Valganciclovir
Verified date | December 2007 |
Source | University of Washington |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The purpose of the study is to use valganciclovir to define the role of antiviral therapy in suppression of HHV-8 shedding in HHV-8 seropositive men. Our hypothesis is that valganciclovir will substantially reduce the frequency of detection and amount of HHV-8 in the mouth.
Status | Completed |
Enrollment | 32 |
Est. completion date | March 2005 |
Est. primary completion date | March 2005 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - 18 years or older - HHV-8 seropositive or previous evidence of HHV-8 shedding - a frequent shedder of HHV-8 - not receiving any drugs with known anti-HHV-8 activity for study duration - able to comply with the study protocol - agree to HIV testing Exclusion Criteria: - history of evidence of CMV disease - hypersensitivity to ganciclovir or valganciclovir - use of high-dose acyclovir, valacyclovir, famciclovir, ganciclovir, foscarnet, or cidofovir - neutropenia - renal insufficiency with serum creatinine greater than 1.5mg.ml or CrCl less than 60 - AST or ALT greater than 5 times upper limit of normal - concurrent administration of medications which are often associated with severe neutropenia or thrombocytopenia - concurrent administration of probenecid or didanosine |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
United States | University of Washington Virology Research Clinic | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
University of Washington | Hoffmann-La Roche |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The reduction in percent days on which HHV-8 is detected on versus off valganciclovir. The quantitative reduction in the HHV-8 DNA detected by PCR on versus off valganciclovir. | 19 weeks | No | |
Secondary | The frequency of neutropenia, defined as ANC less than 500. The frequency of thrombocytopenia, defined as platelets less than 75,000. | 19 weeks | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00380770 -
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
|
Phase 4 |